# Dominik Escher

> Dominik Escher is a Series A investor at ESBATech backing Biotechnology and Therapeutics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ESBATech](https://shizune.co/investors/profile/esbatech)
- Total investments: 6
- Last investment: Jun 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dominik-escher-399a536/

Dominik Escher is a Series A investor at ESBATech focused on Biotechnology and Therapeutics. Dominik is a founding partner of Pureos and a co-founder and Executive Chairman of CDR-Life. He is also president of the Swiss Biotech Association. Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novelantibody fragments from discovery to maturity, delivering multiple clinically successful products (e.g., Brolucizumab). Dominik obtained his PhD in Molecular Biology from the University of Zurich.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 83% |
| Therapeutics | 4 | 67% |
| Health Care | 2 | 33% |
| Medical | 1 | 17% |
| Medical Device | 1 | 17% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Seed | 2 | 33% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 33% |
| Switzerland | 2 | 33% |
| United States | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tavo Biotherapeutics | Tavo Biotherapeutics is a biotech company that develops injection therapies for eye diseases. | $17M | Series A | Jun 02, 2026 |  |
| PulseSight Therapeutics | PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness. |  | Seed | Feb 28, 2024 |  |
| Araris Biotech | Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/orcell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents. | $24M | Series A | Oct 04, 2022 |  |
| Engimmune Therapeutics | Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors. | $15.8M | Seed | May 03, 2022 |  |
| Eyevensys | Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures. | $30M | Series B | Jan 08, 2020 |  |
| PulseSight Therapeutics | PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness. |  | Series A |  |  |

6 of 6 investments shown.

## Co-investors
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [b2venture](https://shizune.co/investors/profile/btovpartners) — VC Fund, 1 deal together
- [Institute for Follicular Lymphoma Innovation](https://shizune.co/investors/profile/follicular-lymphoma-innovation) — VC Fund, 1 deal together
- [Global health sciences venture fund](https://shizune.co/investors/profile/global-health-sciences-venture-fund) — VC Fund, 1 deal together

## About ESBATech

VC Fund · Schlieren, Switzerland

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech isfocused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

2 contacts available at ESBATech.

| Name | Title | Profile |
| --- | --- | --- |
| Dominik Escher | CEO & Co- Founder | https://shizune.co/investors/profile/dominik-escher |
| Martin Gertsch | Chief Financial Officer | https://shizune.co/investors/profile/martin-gertsch |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Dominik Escher invest in?

Dominik Escher invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dominik Escher last invest?

The most recent investment recorded for Dominik Escher closed in Jun 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co